Mounjaro vs Wegovy: Which GLP-1 Medication Is Right for You?

The fundamental difference between Mounjaro and Wegovy lies in their mechanism of action. Wegovy contains semaglutide, which is a GLP-1 receptor agonist — it mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and regulate blood sugar. It targets one hormonal pathway. Mounjaro contains tirzepatide, which is a dual GIP/GLP-1 receptor agonist. In addition to all the GLP-1 effects that Wegovy provides, Mounjaro also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP plays a role in insulin secretion, fat metabolism, and energy balance. This dual action is believed to be the reason tirzepatide produces greater weight loss in clinical trials. Think of it this way: if semaglutide turns one dial to reduce hunger and improve metabolism, tirzepatide turns two dials simultaneously. The result is enhanced appetite suppression and metabolic improvement that translates to greater average weight loss.

Clinical trial data allows a clear comparison between these two medications: Semaglutide (Wegovy): The STEP trials showed average weight loss of 15-17% of body weight over 68 weeks at the 2.4mg dose. Approximately 86% of participants lost at least 5% of body weight, and about one-third lost 20% or more. Tirzepatide (Mounjaro/Zepbound): The SURMOUNT trials demonstrated average weight loss of 20-25% of body weight over 72 weeks at the 15mg dose. Over 90% of participants lost at least 5% of body weight, and more than one-third lost over 25%. Both medications show significant improvements in blood pressure, cholesterol, blood sugar, and waist circumference. Both are administered as once-weekly subcutaneous injections. Side effect profiles are similar, with GI symptoms (nausea, diarrhea, constipation) being the most common for both. At A Touch Above MedSpa, both semaglutide and tirzepatide are available. Dr. Shailender Singh evaluates your individual health profile to recommend the medication most likely to produce the best results for your specific situation.

Choosing between Mounjaro and Wegovy is not simply about picking the medication with the higher average weight loss number. Several factors influence which medication is best for each individual patient. Tirzepatide may be preferred for patients with significant weight to lose (BMI 35+), patients with insulin resistance or type 2 diabetes (due to the enhanced glucose-lowering effect of dual agonism), and patients who have not achieved desired results with semaglutide alone. Semaglutide may be preferred for patients who have responded well to GLP-1-only therapy, patients who prefer a medication with a longer track record, and as a first-line option for patients new to GLP-1 therapy. During your consultation at A Touch Above MedSpa, Dr. Singh reviews your complete health picture — medical history, current medications, metabolic markers, and weight loss goals — to make a personalized recommendation. Some patients start on semaglutide and later transition to tirzepatide for enhanced results, while others begin with tirzepatide from the start.